Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $6.31, $0.72 better than the analyst estimate of $5.59. Revenue for the quarter came in at $15.56 billion versus the consensus estimate of $14.67 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2025 EPS of $21.75-$23.00, versus the consensus of $21.98. Eli Lilly & Co. sees FY2025 revenue of $60-62 billion, versus the consensus of $60.09 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• TNL Mediagene faces Nasdaq delisting over bid price and equity rules